Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

2.66 

0.10 3.9%

as of Nov 25 '22

52 Week Range:

1.98 2.90


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) -0.19
0.59
0.69
0.72
0.62
0.75
growth rate 100.0% 17.0% 4.4% -13.9% 21.0%
Earnings BIT 344.90
298.00
254.00
203.70
281.10
280.80
214.40
224.90
231.30
growth rate -13.6% -14.8% -19.8% 38.0% -0.1% -23.7% 4.9% 2.9%
Avg.PE -26.50
29.76
14.85
14.85
14.85
14.85
growth rate 100.0% -50.1% 0.0% 0.0% 0.0%
ROA 0.34
-3.02
-2.48
-5.69
4.33
5.94
0.27
3.05
3.16
growth rate -100.0% 0.0% 0.0% 100.0% 37.2% -95.5% 1,029.6% 3.6%
ROE 31.87
-47.93
11.44
14.11
0.62
6.96
6.99
growth rate -100.0% 100.0% 23.3% -95.6% 1,022.6% 0.4%
ROIC 5.64
-0.06
6.75
8.21
1.72
4.40
4.57
growth rate -100.0% 100.0% 21.6% -79.1% 155.8% 3.9%
Cur. Ratio 2.13
2.25
2.65
2.57
2.71
2.73
2.44
2.30
1.95
growth rate 5.6% 17.8% -3.0% 5.5% 0.7% -10.6% -5.7% -15.2%
Quick Ratio 1.42
1.44
1.77
1.66
1.73
1.72
1.64
1.67
1.34
growth rate 1.4% 22.9% -6.2% 4.2% -0.6% -4.7% 1.8% -19.8%
Leverage 94.06
2.82
2.49
2.26
2.31
2.25
2.17
growth rate -68.9% -11.7% -9.2% 2.2% -2.6% -3.6%
Balance Sheet Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 308.20
241.90
232.10
233.70
269.00
253.70
283.80
289.50
301.50
growth rate -21.5% -4.1% 0.7% 15.1% -5.7% 11.9% 2.0% 4.2%
Acct.Payable 101.20
80.30
114.50
111.60
122.00
89.10
90.50
98.20
116.70
growth rate -20.7% 42.6% -2.5% 9.3% -27.0% 1.6% 8.5% 18.8%
Cur.Assets 895.30
769.40
757.20
770.80
875.10
903.20
968.30
1,178.50
1,110.80
growth rate -14.1% -1.6% 1.8% 13.5% 3.2% 7.2% 21.7% -5.7%
Total Assets 4,561.80
3,962.80
3,791.40
3,513.90
3,800.90
3,660.40
3,609.80
3,766.50
3,674.00
growth rate -13.1% -4.3% -7.3% 8.2% -3.7% -1.4% 4.3% -2.5%
Cash 271.40
234.00
273.00
264.10
289.30
315.60
385.80
565.40
463.40
growth rate -13.8% 16.7% -3.3% 9.5% 9.1% 22.2% 46.6% -18.0%
Inventory 253.70
250.10
228.90
247.50
284.50
303.30
281.80
297.10
308.80
growth rate -1.4% -8.5% 8.1% 15.0% 6.6% -7.1% 5.4% 3.9%
Cur.Liabilities 387.00
344.90
285.60
300.00
338.50
330.90
397.30
513.20
569.20
growth rate -10.9% -17.2% 5.0% 12.8% -2.3% 20.1% 29.2% 10.9%
Liabilities 6,694.30
6,137.40
4,010.20
2,267.70
2,277.10
2,043.20
2,048.80
2,095.80
1,979.20
growth rate -8.3% -34.7% -43.5% 0.4% -10.3% 0.3% 2.3% -5.6%
LT Debt 4,665.30
4,214.10
3,476.90
1,714.70
1,719.90
1,558.80
1,445.30
1,377.50
1,202.70
growth rate -9.7% -17.5% -50.7% 0.3% -9.4% -7.3% -4.7% -12.7%
Equity -2,132.50
-2,174.60
-218.80
1,246.20
1,523.80
1,617.20
1,561.00
1,670.70
1,694.80
growth rate 0.0% 0.0% 100.0% 22.3% 6.1% -3.5% 7.0% 1.4%
Common Shares 1,951.00
1,951.00
1,951.00
1,376.00
1,954.00
240.70
242.90
245.50
247.00
growth rate 0.0% 0.0% -29.5% 42.0% -87.7% 0.9% 1.1% 0.6%
Cash Flow Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 36.90
44.70
36.70
66.50
82.70
72.10
61.40
86.20
94.10
growth rate 21.1% -17.9% 81.2% 24.4% -12.8% -14.8% 40.4% 9.2%
Cash Dividends 26.30
26.30
26.30
26.30
74.90
79.90
62.90
85.80
growth rate 0.0% 0.0% 0.0% 184.8% 6.7% -21.3% 36.4%
Cash From OA 229.10
147.30
100.30
74.90
306.60
352.00
401.80
399.50
305.90
growth rate -35.7% -31.9% -25.3% 309.4% 14.8% 14.2% -0.6% -23.4%
FCF per Share 0.03
0.05
0.12
0.14
0.12
0.12
growth rate 66.7% 140.0% 16.7% -14.3% 0.0%
Sale Purchase of Stock 1,764.30
1,764.30
1,764.30
1,764.30
growth rate 0.0% 0.0% 0.0%
FCF 190.00
102.00
63.00
7.00
222.00
279.00
340.00
313.00
212.00
growth rate -46.3% -38.2% -88.9% 3,071.4% 25.7% 21.9% -7.9% -32.3%
Income Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 1,700.70
1,733.90
1,650.40
1,688.30
1,764.60
1,832.10
1,827.20
1,894.30
2,038.30
growth rate 2.0% -4.8% 2.3% 4.5% 3.8% -0.3% 3.7% 7.6%
Op.Income 344.90
298.00
254.00
203.70
281.10
280.80
214.40
224.90
231.30
growth rate -13.6% -14.8% -19.8% 38.0% -0.1% -23.7% 4.9% 2.9%
IBT -141.60
-258.20
-110.30
-125.80
164.00
201.20
18.90
174.70
151.30
growth rate 0.0% 0.0% 0.0% 100.0% 22.7% -90.6% 824.3% -13.4%
Net Income -173.70
-286.50
-93.40
-202.80
158.40
221.60
9.80
112.50
117.60
growth rate 0.0% 0.0% 0.0% 100.0% 39.9% -95.6% 1,048.0% 4.5%
EPS 0.01
-0.07
-0.05
-0.15
0.08
0.11
0.01
0.06
0.06
growth rate -100.0% 0.0% 0.0% 100.0% 37.5% -90.9% 500.0% 0.0%
Gross Profit 947.20
913.70
853.00
909.90
951.90
977.10
955.60
1,020.10
1,123.80
growth rate -3.5% -6.6% 6.7% 4.6% 2.7% -2.2% 6.8% 10.2%
R&D 32.00
37.20
40.10
36.90
40.30
49.30
53.80
81.20
94.60
growth rate 16.3% 7.8% -8.0% 9.2% 22.3% 9.1% 50.9% 16.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 69.45
46.20
46.20
59.10
59.10
growth rate -33.5% 0.0% 27.9% 0.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 332.10
301.50
301.50
348.30
348.30
growth rate -9.2% 0.0% 15.5% 0.0%
Acct.Payable 274.90
116.70
116.70
301.70
301.70
growth rate -57.6% 0.0% 158.5% 0.0%
Cur.Assets 1,128.80
1,110.80
1,110.80
963.30
963.30
growth rate -1.6% 0.0% -13.3% 0.0%
Total Assets 3,743.00
3,674.00
3,674.00
3,685.60
3,685.60
growth rate -1.8% 0.0% 0.3% 0.0%
Cash 501.10
463.40
463.40
271.60
271.60
growth rate -7.5% 0.0% -41.4% 0.0%
Inventory 293.00
308.80
308.80
319.70
319.70
growth rate 5.4% 0.0% 3.5% 0.0%
Cur.Liabilities 455.50
569.20
569.20
647.70
647.70
growth rate 25.0% 0.0% 13.8% 0.0%
Liabilities 2,031.70
1,979.20
1,979.20
2,102.20
2,102.20
growth rate -2.6% 0.0% 6.2% 0.0%
LT Debt 1,365.20
1,202.70
1,202.70
1,206.30
1,206.30
growth rate -11.9% 0.0% 0.3% 0.0%
Equity 1,711.30
1,694.80
1,694.80
1,583.40
1,583.40
growth rate -1.0% 0.0% -6.6% 0.0%
Common Shares 246.80
247.00
247.00
250.50
250.50
growth rate 0.1% 0.0% 1.4% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 21.80
25.25
25.25
32.05
32.05
growth rate 15.8% 0.0% 26.9% 0.0%
Cash Dividends 26.80
16.10
16.10
29.45
29.45
growth rate -39.9% 0.0% 82.9% 0.0%
Cash From OA 65.50
87.45
87.45
56.25
56.25
growth rate 33.5% 0.0% -35.7% 0.0%
Sale Purchase of Stock
growth rate
FCF 43.70
62.20
62.20
24.20
24.20
growth rate 42.3% 0.0% -61.1% 0.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 504.00
515.15
515.15
522.25
522.25
growth rate 2.2% 0.0% 1.4% 0.0%
Op.Income 69.45
46.20
46.20
59.10
59.10
growth rate -33.5% 0.0% 27.9% 0.0%
IBT 56.05
19.60
19.60
23.05
23.05
growth rate -65.0% 0.0% 17.6% 0.0%
Net Income 42.90
15.90
15.90
24.15
24.15
growth rate -62.9% 0.0% 51.9% 0.0%
Gross Profit 277.75
284.15
284.15
281.80
281.80
growth rate 2.3% 0.0% -0.8% 0.0%
R&D 20.45
26.85
26.85
23.60
23.60
growth rate 31.3% 0.0% -12.1% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (28.20)

YOY Growth Grade:

E (17.41)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 56.09 57.83
EPS / Growth 0.05

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 39.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 39.5% 39.5% 39.5%
Future PE 0.01 45.05 45.05
Future EPS 1.29 1.29 1.29
Value Price
MOS %
0.00
-99.9%
14.33
438.7%
14.33
438.7%
MOS Price 0.00 7.16 7.16
IRT 8.53 8.53 8.53

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.